Medication for Opioid Use Disorder Data

Note: We update this information every month.

Note: Here we use data from Rhode Island Department of Health (RIDOH), Substance Abuse and Mental Health Services Administration (SAMHSA), and Rhode Island Dept of Behavioral Healthcare, Developmental Disabilities and Hospitals (BHDDH).


The number of Rhode Islanders on Medication for Opioid Use Disorder (MOUD) is slowly declining

Buprenorphine/naloxone, naltrexone, and methadone are evidence-based treatments for opioid addiction (also called opioid use disorder). A key initiative under the Governor’s action plan is to increase the number of people accessing medication for opioid use disorder (MOUD). Learn more about our action plan to address addiction and overdose in Rhode Island.

Source (RIDOH) Source (BHDDH) Source (VIVITROL)




Buprenorphine treatment capacity in Rhode Island has more than doubled since 2014

As of the start of 2023, the DEA eliminated the requirement of the X-Waiver to treat Opioid Use Disorder. This change allows any physician or healthcare professional with a DEA license to prescribe buprenorphine. Due to this change, the graph below stops displaying data beyond December 2022.

Source (RIDOH)


Medication for Opioid Use Disorder (MOUD) options are available throughout Rhode Island

Find a treatment provider in your community on our Find Treatment page.

Source (SAMHSA Buprenorphine) Source (SAMHSA Methadone) Vivitrol Treatment Locator